Breaking News

Almac Expands Crystallization Capabilities

A new Empyrean X-ray powder diffractometer is part of the investment.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Almac Sciences has invested approximately $485,000 in an automated crystallization platform to support solid form screening of polymorphs, salts and crystals in addition to crystallization of amorphous materials. A new Empyrean X-ray powder diffractometer, which allows X-ray powder diffraction analysis of samples, represents an additional $345,000 investment by the company.   The ChemSpeed Swing Crystal platform automates many common crystallisation operations, which reduces overall duration f...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters